PROKIDNEY CORP.
PROK evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PROK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PROK
ProKidney Corp. is a clinical-stage biotechnology company developing rilparencel, a renal autologous cell therapy for chronic kidney disease, with a Phase 3 trial underway and cash runway into mid-2027.
Key risk: Clinical trial failure
BioSniper Score
Based on 6 of 6 signals
Market Cap
$730.5M
Cash Runway
8.1 moLead Asset
react (Phase 3)
Next Catalyst
Phase3_Topline · Dec 1, 2029Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials · 1 catalyst for PROKIDNEY CORP..
ProKidney Corp. is a clinical-stage biotechnology company developing rilparencel, a renal autologous cell therapy for chronic kidney disease, with a Phase 3 trial underway and cash runway into mid-2027.
- ProKidney's lead product candidate is rilparencel, a renal autologous cell therapy (REACT) being evaluated in a Phase 3 randomized controlled trial for type 2 diabetes patients with chronic kidney disease [sec_mda · as of 2026-08-10].
- As of June 30, 2026, the company reported cash and equivalents of $74.9 million, with an additional $175.0 million available under a sales agreement [sec_mda · as of 2026-08-10].
- The company expects existing cash to fund operations into mid-2027, but notes this estimate could change and it may exhaust capital sooner [sec_mda · as of 2026-08-10].
- ProKidney has an accumulated deficit of $1,011.2 million in shareholders' equity as of June 30, 2026, reflecting years of R&D spending without product revenue [sec].
- The company has completed two Phase 2 trials of rilparencel (NCT02836574 and NCT05018416) and is now focused on the Phase 3 PROACT-1 trial [catalyst].
What works
- ProKidney has a clear regulatory pathway: the FDA has indicated that the Phase 3 PROACT-1 trial alone could support a BLA submission and full approval, with eGFR slope as a surrogate endpoint for accelerated approval [sec · filed 2024-09-03].
- The company has a substantial cash position ($74.9M as of June 30, 2026) plus a $175.0M at-the-market facility, providing financial flexibility to advance its pivotal trial [sec_mda · as of 2026-08-10].
- Rilparencel targets a large unmet need in chronic kidney disease, with prior Phase 2 data showing improvement in renal function progression rate [catalyst].
What to weigh
- ProKidney has no approved products and has never generated material revenue from product sales; it is entirely dependent on the success of rilparencel [sec_mda · as of 2026-08-10].
- The company's accumulated deficit is $1,011.2 million as of June 30, 2026, and it expects expenses to increase substantially as clinical trials progress [sec].
- Cash runway is only projected into mid-2027, and the company acknowledges it could exhaust capital sooner than expected if assumptions prove wrong [sec_mda · as of 2026-08-10].
- The Phase 3 trial is still ongoing and there is no guarantee of positive topline results or eventual regulatory approval [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
ProKidney expects cash to fund operations into mid-2027.
“We expect that our existing cash, cash equivalents and marketable securities held at June 30, 2026, will enable us to fund our operating expenses and capital expenditure requirements into mid-2027.”
SEC MD&A · August 10, 2026
The FDA has indicated that the Phase 3 PROACT-1 trial could be sufficient for BLA submission.
“the Company's beliefs that its PROACT 1 trial could be sufficient to support a potential BLA submission and full regulatory approval, eGFR slope can be used as a surrogate endpoint on an accelerated approval pathway for rilparencel”
SEC filings · September 3, 2024
There is $175.0 million remaining available under the 2025 Sales Agreement.
“As of June 30, 2026, there was approximately $175.0 million remaining available to be sold under the 2025 Sales Agreement.”
SEC MD&A · August 10, 2026
Catalyst timeline
- 2029-12-01 · Phase3_Topline — Topline results from the Phase 3 randomized controlled study of REACT in subjects with type 2 diabetes and chronic kidney disease.
Risks & what to watch (4)›
Key risks
- Clinical trial failure — The Phase 3 PROACT-1 trial may not meet its primary endpoint, delaying or preventing approval [sec_mda · as of 2026-08-10].
- Cash runway uncertainty — Cash runway is only into mid-2027; the company may need additional financing, which could be dilutive [sec_mda · as of 2026-08-10].
- Regulatory dependency — Approval relies on FDA acceptance of eGFR slope as a surrogate endpoint; any change could derail the pathway [sec · filed 2024-09-03].
- Single product focus — ProKidney has only one product candidate in development, increasing business risk if it fails [sec_mda · as of 2026-08-10].
What to watch
- Topline data from the Phase 3 PROACT-1 trial, expected by Q3 2027 per prior guidance [sec · filed 2024-09-03].
- Cash burn rate and any future capital raises or use of the $175.0M ATM facility [sec_mda · as of 2026-08-10].
- Regulatory updates from the FDA regarding the accelerated approval pathway for rilparencel [sec · filed 2024-09-03].
- Any partnership or licensing deals to expand the pipeline or reduce financial risk [sec_mda · as of 2026-08-10].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run PROKIDNEY CORP. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PROKIDNEY CORP. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
8.1 months
OCF -$40M · Net income -$28M
Lead: Phase 3
2 candidates
1 upcoming, next in ~1189d
0 buys · 6 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
67
Total value held
$69.2M
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 12,341,266 | $22.1M |
| morgan stanley | 8,955,967 | $16.0M |
| vanguard capital management llc | 2,293,874 | $4.1M |
| millennium management llc | 2,271,577 | $4.1M |
| blackrock, inc. | 1,387,116 | $2.5M |
| renaissance technologies llc | 1,250,794 | $2.2M |
| geode capital management, llc | 1,230,409 | $2.2M |
| marshall wace, llp | 1,011,744 | $1.8M |
| woodline partners lp | 1,000,000 | $1.8M |
| bank of america corp /de/ | 753,412 | $1.3M |
Showing top 10 of 67 institutional holders of PROKIDNEY CORP.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 16.1%
- Days to cover
- 21.3
- Shares short
- 16,683,004
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PROK short interestGovernance
Frequently asked questions
What is the AI investment thesis for PROKIDNEY CORP.?
ProKidney Corp. is a clinical-stage biotechnology company developing rilparencel, a renal autologous cell therapy for chronic kidney disease, with a Phase 3 trial underway and cash runway into mid-2027.
What is PROKIDNEY CORP.'s lead drug candidate?
PROKIDNEY CORP.'s most advanced tracked candidate is react (Phase 3) for CKD due to congenital anomalies of the kidney and urinary tract (CAKUT).
What is PROKIDNEY CORP.'s next catalyst?
PROKIDNEY CORP.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized Controlled Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type" — expected December 1, 2029.
Who is the CEO of PROKIDNEY CORP.?
Dr. Bruce Culleton M.D. is the chief executive officer of PROKIDNEY CORP. (PROK).
Where is PROKIDNEY CORP. headquartered?
PROKIDNEY CORP. (PROK) is headquartered in Winston-Salem, NC, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.